A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
A Phase 1, open label, multi center, dose escalation and expansion study will assess the
safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with
advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose
(MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and
preliminary efficacy of SCR-6920 in participants with advanced solid tumors and
relapsed/refractory non-Hodgkin lymphoma(NHL).